Fintel reports that on Oct 20, 2023 Benchmark initiated coverage on Agilon Health (NYSE:AGL) with Buys recommendation.
The analyst’s price forecast suggests a 51.44% upside
As of October 5, 2023, Agilon Health’s one-year average price target is 29.29. Estimates range from a low of $21.21 to a high of $43.05. The average price target represents a 51.44% increase from the last reported close price of 19.34.
See our ranking of companies with the largest price target growth.
Estimated annual revenue for Agilon Health is 3,950 million, an increase of 7.63%. Estimated annual non-GAAP EPS is -0.01.
What is the mood of the fund?
There are 518 funds or institutions reporting positions in Agilon Health. This is an increase of 7 owners or 1.37% in the last quarter. Average portfolio weight by all means devoted to AGL was 0.31%, down from 26.41%. Total shares held by institutions increased over the past three months by 4.76% to 538,987 thousand shares. AGL’s put/call ratio is 0.34, indicating a bullish outlook.
What are other shareholders doing?
Clayton, Dubilier & Rice owns 100,000K shares representing 24.66% ownership of the company. In its previous filing, the firm reported that it owns 194,611 thousand shares, representing reduction of 94.61%. The company decreased its portfolio allocation in AGL by 49.22% in the last quarter.
Capital World Investors owns 51,348 thousand shares representing 12.66% ownership of the company. In its previous filing, the firm reported that it owns 42,436 thousand shares, representing raise from 17.36%. The company decreased its portfolio allocation in AGL by 17.79% in the last quarter.
Wellington Management Group Llp owns 38,157 thousand shares representing 9.41% of the company’s ownership. In its previous filing, the firm reported that it owns 20,346 thousand shares, representing raise from 46.68%. The company increased its portfolio allocation in AGL by 828.03% in the last quarter.
VGHCX – Vanguard Health Care Fund Investor Shares owns 19,043K shares representing 4.70% of the company’s ownership. In its previous filing, the firm reported that it owns 14,265,000 shares, representing raise from 25.09%. The company increased its portfolio allocation in AGL by 6.84% in the last quarter.
ANEFX – NEW ECONOMY FUND owns 17,247 thousand shares, representing 4.25% ownership of the company. In its previous filing, the firm reported that it owns 14,503 thousand shares, representing raise from 15.91%. The company increased its portfolio allocation in AGL by 5.40% in the last quarter.
Basic health information about Agilon
(This description is provided by the company.)
agilon health is transforming healthcare by providing community physicians with the resources and expertise they need to innovate in the payment and delivery of senior care. agilon health empowers physicians to create their own Medicare-focused, globally capitalized line of business. The agilon Total Care model is powered by its purpose-built platform and enabled through a growing nationwide network of like-minded physician partners. With agilon, physicians are freed from the constraints of the transactional fee-for-service reimbursement model and are able to practice team-based, coordinated care to serve the individual needs of their elderly patients and transition to a sustainable and predictable, long-term business model . The rapidly growing appeal of the agilon platform, partnership model and network of leading community physicians has allowed the company to expand to 17 local communities with 16 leading physician groups, as well as a network of physicians in Hawaii in less than five years.
Fintel is one of the most comprehensive investment research platforms available to individual investors, traders, financial advisors and small hedge funds.
Our data spans the globe and includes fundamentals, analyst reports, fund ownership and sentiment data, options sentiment, insider trading, options flow, unusual options trades and much more. Additionally, our exclusive stock picks are powered by advanced, proven quantitative models for enhanced returns.
Click to learn more
This story originally appeared on Fintel.
The views and opinions expressed herein are those of the author and do not necessarily reflect those of Nasdaq, Inc.